Ganem v. Invivo Therapeutics Holdings Corp., 845 F.3d 447

Background

InVivo Therapeutics (a biotech company) received an FDA letter in March 2013 approving an IDE "with conditions" to begin a staged, five‑patient early feasibility study of a biopolymer scaffold for spinal cord injury; FDA listed 13 required corrections and 8 recommended study design changes.
On April 5, 2013 InVivo issued a press release saying the FDA "approved" the IDE, the company intended to begin the study "in the next few months," expected the pilot to run ~15 months, and expected to have data to the FDA by end of 2014; the release did not detail the FDA conditions or recommended modifications but included a safe‑harbor statement.
A May 9, 2013 press release reiterated timeline projections (start mid‑2013; submit data by end of 2014). Share price rose after the April release; no alleged price effect from May release.
On August 27, 2013 new management announced a delayed enrollment schedule (first patient Q1 2014 and ~21 months to complete enrollment), and the stock price fell substantially in late August 2013.
Plaintiff Ganem sued under § 10(b)/Rule 10b‑5 (and § 20(a) derivative claim against CEO Reynolds), alleging the April and May press releases were materially false or misleading because they omitted the FDA’s conditions, recommendations, and staged‑enrollment requirement which made the projected timeline infeasible.
District court dismissed for failure to plead a material misrepresentation or omission and scienter; First Circuit affirmed, holding plaintiff failed to plead actionable misstatements or omissions (and thus § 20(a) claim failed).

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Whether April and May 2013 press releases contained materially false or misleading statements or omissions under § 10(b)/Rule 10b‑5	Ganem: Omitting the FDA’s required corrections, recommended design changes, and staged enrollment rendered the timeline statements ("next few months," "mid‑2013," ~"15 months," "data by end of 2014") materially misleading because those conditions made the timeline impossible	InVivo: Press releases accurately reported FDA approval to begin a staged study; FDA letter expressly allowed enrollment of one subject "at this time," stated 5 subjects could be enrolled over a minimum 15 months, and the recommended changes were not required; statements were forward‑looking and accompanied by cautionary language	Held: No actionable misrepresentation or omission. Plaintiff pleaded only hindsight/speculation; FDA letter permitted near‑term start and a 15‑month minimum, so statements were not rendered false or misleading
Whether omissions about recommended (non‑required) FDA modifications made statements misleading	Ganem: Recommendations were practically necessary to support future studies, so omission was misleading	InVivo: Recommendations were expressly optional ("we recommend, but do not require") and thus not a required disclosure	Held: Recommendations were non‑binding; failure to disclose them is not actionable absent facts showing timeline was impossible
Whether forward‑looking timeline statements are protected (bespeaks‑caution / statutory safe harbor)	Ganem: Not applicable; statements were misleading despite safe‑harbor language	InVivo: Statements were accompanied by cautionary language and risk disclosures; bespeaks‑caution applies	Held: Court did not need to decide safe‑harbor applicability because plaintiff failed to allege a material misrepresentation or omission in any event
Whether § 20(a) control‑person claim against CEO could proceed absent a viable § 10(b) claim	Ganem: Reynolds is a controlling person liable for any primary violation	InVivo: No primary § 10(b) violation, so no derivative liability	Held: § 20(a) claim dismissed because no predicate § 10(b) violation was pleaded

Key Cases Cited

Tellabs Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (standard for pleading scienter and evaluating securities fraud allegations)
Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (omissions can make statements misleading; materiality standard)
ACA Financial Guaranty Corp. v. Advest, Inc., 512 F.3d 46 (PSLRA pleading requirements: specify statements and reasons why misleading)
Hill v. Gozani, 638 F.3d 40 (when a company speaks it cannot omit facts necessary to prevent misleading statements; PSLRA context)
In re Ariad Pharmaceuticals, Inc. Securities Litigation, 842 F.3d 744 (elements of a § 10(b)/Rule 10b‑5 claim)
Shaw v. Digital Equipment Corp., 82 F.3d 1194 (bespeaks‑caution doctrine; no fraud‑by‑hindsight)